Less Grey Imaging

Less Grey Image是一家有前景的公司，旨在将先进的超声成像商业化，成为一种用于疾病诊断的软件产品。这项技术被称为超分辨率超声成像(SRUI)，它提供了整个器官的微观细节图，这是器官结构和功能可视化方面的一次飞跃。虽然这项技术可以用于诊断几种疾病，但我们已经确定，前列腺癌是一种主要疾病，涉及很大一部分男性人口，因此构成了我们技术的巨大市场。我们的目标是创造一种软件形式的医疗设备/产品，作为现有诊断检查的辅助工具，为前列腺癌提供准确的诊断。这将有助于识别和定位目前被空间精确度遗漏的重大癌症。此外，它还将帮助识别大量接受不必要的活检或治疗的患者，从而降低医疗成本、患者风险和不便。我们受保护的创新不需要新的硬件，并确保使用当前的超声设备生成前列腺的SRUI图，并在可行的患者检查时间(分钟)内生成。Less Grey软件最初可以用来正确识别需要活组织检查的患者，此外还可以提供患者监测和改进的治疗计划。此外，我们还设想将我们的技术应用于大量其他癌症和心血管疾病以及其他疾病。继Grey在ICURE计划中取得的成功并建议在Options环形交叉路口进行分拆之后，Innovate UK资助的项目旨在通过提供明确的商业计划、最终确定产品设计和临床使用，在一年内减少Grey的投资。我们的计划是在四年内打入最赚钱的美国市场。为了减轻风险并降低与西方国家冗长监管程序相关的成本，我们将把亚洲市场作为首选。采用的方向对超声波技术非常有利，并将通过产生现金流在Grey较少的头几年为公司提供稳定。

Less Grey Imaging is a prospective company that aims to commercialise advanced ultrasound imaging into a software product for disease diagnosis. The technology is called super-resolution ultrasound imaging (SRUI) and provides maps of entire organs in microscopic detail, which constitutes a leap in the visualisation of the structure and function of organs. While this technology can be used for the diagnosis of several diseases, we have identified that prostate cancer is a major disease that concerns a large part of the male population, and thus constitutes a large market for our technology. Our intention is to create a medical device/product in the form of software that will work as an adjunct to existing diagnostic examinations to provide accurate diagnosis of prostate cancer. This will help identify & localise significant cancers that are currently missed with spatial accuracy. In addition, it will help identify the large number of patients that undergo unnecessary biopsy or treatment, thus reducing healthcare costs, patient risk, and inconvenience.Our protected innovation does not require new hardware and ensures that the SRUI maps of the prostate are generated with current ultrasound equipment, and within feasible patient examination times (minutes). The Less Grey software can be used initially to identify correctly patient in need of biopsy and additionally provide patient surveillance and enable improved treatment planning. Further, we envision the application of our technology to a large number of other cancers and cardiovascular disease as well as other diseases.Following Less Grey's success during the ICURe programme with the recommendation to spin out at the Options Roundabout, the Innovate UK funded project is designed to make Less Grey investable within one year, by providing a clear business plan, finalising product design and clinical usage. Our plan is to enter the most lucrative USA market within four years. To mitigate the risk and reduce the costs associated with the lengthy regulatory procedures in the western countries, we will engage with an Asian market as a first choice. The adopted direction is highly favourable for ultrasound technologies and will provide company stability during the first years of Less Grey by generating cash flow.